Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/18/2025 | $9.00 | Buy | H.C. Wainwright |
| 1/28/2025 | $9.00 | Buy | Guggenheim |
| 5/13/2022 | $25.00 → $15.00 | Overweight | Cantor Fitzgerald |
| 11/24/2021 | $35.00 → $25.00 | Buy | HC Wainwright & Co. |
4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)
10-Q - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
10-Q/A - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
10-K/A - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)
4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)
4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)
Updated data from ongoing open-label Phase 1b trial demonstrated a mean 12-month eGFR of approximately 68 mL/min/1.73 m2 post-transplant for patients on tegoprubart Company on track to report topline results from Phase 2 BESTOW trial in kidney transplantation in November 2025 Cash, cash equivalents and short-term investments of $107.6 million as of June 30, 2025 IRVINE, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its second quarter 2025 operating and financial results and reviewed recent business highlights. "We are proud to enter the second half of the year with strong momentum as we have achieved all of our key miles
Data from patients who remained on tegoprubart for a year showed overall mean 12-month eGFR of approximately 68 mL/min/1.73 m² post-transplant Preliminary iBox data, a key biomarker of kidney function and immunologic response, supports that tegoprubart may improve 5-year graft survival vs. current standard of care Tegoprubart continues to be well tolerated with no cases of death, graft loss, drug related tremor, or new-onset diabetes Conference call to be held today at 4:30 p.m. ET IRVINE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced updated data from the Company's ongoing open-label Phase 1b trial evaluating tegoprubar
IRVINE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that the company will host a conference call and webcast on Wednesday, August 6, 2025 at 4:30 p.m. ET to discuss updated clinical data from its ongoing open-label Phase 1b study evaluating tegoprubart for the prevention of rejection in subjects undergoing kidney transplantation. These data, from approximately 30 kidney transplant recipients, are being presented at the World Transplant Congress (WTC) in San Francisco, CA on August 6, 2025. To join the conference call, please dial 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. The conferen
H.C. Wainwright resumed coverage of Eledon Pharmaceuticals with a rating of Buy and set a new price target of $9.00
Guggenheim initiated coverage of Eledon Pharmaceuticals with a rating of Buy and set a new price target of $9.00
Cantor Fitzgerald resumed coverage of Eledon Pharmaceuticals with a rating of Overweight and set a new price target of $15.00 from $25.00 previously
Enrolled 12 participants in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of kidney rejection Tegoprubart used as a component of the immunosuppressive treatment regimen following the first-ever transplant of a kidney from a genetically modified pig to a human Additional data from 11 participants in Phase 1b trial in kidney transplantation demonstrated that tegoprubart was generally safe and well tolerated, successfully prevented rejection and permitted above historical average post-transplant kidney function IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its fourth quarter and full year 2023 opera
Reported updated data from ongoing Phase 1b trial in kidney transplantation demonstrating tegoprubart treatment successfully prevented kidney transplant rejection and was generally safe and well-tolerated Dosed first participants in Phase 2 BESTOW trial in kidney transplantation Tegoprubart dosed in second-ever pig to human xenotransplant procedure IRVINE, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced a summary of 2023 accomplishments and provided guidance for anticipated upcoming 2024 milestones. 2023 Key Highlights Reported updated data from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection i
Reported updated data from ongoing Phase 1b trial further supporting the potential of tegoprubart as a novel kidney transplant immunosuppressive therapy to prevent rejection and better preserve organ function First participant dosed in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of rejection in kidney transplantation IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its third quarter operating and financial results and reviewed recent business highlights. "We were thrilled recently to report updated results from our ongoing Phase 1b study that continue to validate tegoprubart's potential as an immuno
Data from patients who remained on tegoprubart for a year showed overall mean 12-month eGFR of approximately 68 mL/min/1.73 m² post-transplant Preliminary iBox data, a key biomarker of kidney function and immunologic response, supports that tegoprubart may improve 5-year graft survival vs. current standard of care Tegoprubart continues to be well tolerated with no cases of death, graft loss, drug related tremor, or new-onset diabetes Conference call to be held today at 4:30 p.m. ET IRVINE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced updated data from the Company's ongoing open-label Phase 1b trial evaluating tegoprubar
IRVINE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that the company will host a conference call and webcast on Wednesday, August 6, 2025 at 4:30 p.m. ET to discuss updated clinical data from its ongoing open-label Phase 1b study evaluating tegoprubart for the prevention of rejection in subjects undergoing kidney transplantation. These data, from approximately 30 kidney transplant recipients, are being presented at the World Transplant Congress (WTC) in San Francisco, CA on August 6, 2025. To join the conference call, please dial 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. The conferen
Data from 11 participants demonstrates tegoprubart successfully prevented kidney transplant rejection and was generally safe and well-tolerated Aggregate mean eGFR was above 70 mL/min/1.73m2 at all reported time points after day 90 supporting tegoprubart's potential to protect organ function in patients undergoing kidney transplantation Eledon will host a conference call today at 5:00 p.m. ET IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported results from the Company's ongoing Phase 1b open-label trial evaluating tegoprubart for the prevention of rejection in patients undergoing de novo kidney transplantation. Results
SC 13G/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)
SC 13G - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)
SC 13G - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)